TrialTrials2022

A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.

Byron J Gajewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.